Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Raised to “Moderate Buy” at Raymond James Financial

by · The Markets Daily

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by investment analysts at Raymond James Financial to a “moderate buy” rating in a report issued on Thursday, Zacks reports.

A number of other equities analysts have also issued reports on the company. Mizuho increased their price objective on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Wells Fargo & Company increased their price target on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Royal Bank Of Canada cut shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their price objective for the company from $106.00 to $115.00 in a research note on Monday, July 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $140.00 price objective on shares of Kymera Therapeutics in a report on Wednesday, September 23rd. Finally, Oppenheimer reiterated an “outperform” rating and issued a $125.00 target price on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $134.68.

View Our Latest Report on KYMR

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $112.40 on Thursday. Kymera Therapeutics has a 1-year low of $55.26 and a 1-year high of $130.05. The business’s fifty day moving average price is $114.90 and its two-hundred day moving average price is $99.97. The firm has a market capitalization of $9.35 billion, a PE ratio of -34.69 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. The company had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company’s revenue for the quarter was up 465.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.95) earnings per share. Equities research analysts expect that Kymera Therapeutics will post -3.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider directly owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 15.98% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after buying an additional 98 shares during the period. Proficio Capital Partners LLC boosted its position in Kymera Therapeutics by 1.8% during the 2nd quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company’s stock worth $1,267,000 after acquiring an additional 200 shares during the period. Glenmede Trust Co. NA boosted its position in Kymera Therapeutics by 3.6% during the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after acquiring an additional 235 shares during the period. Cetera Investment Advisers grew its stake in Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after acquiring an additional 252 shares in the last quarter. Finally, Swiss National Bank grew its stake in Kymera Therapeutics by 0.3% during the 1st quarter. Swiss National Bank now owns 94,500 shares of the company’s stock valued at $7,871,000 after acquiring an additional 300 shares in the last quarter.

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs.

Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling.

Further Reading